business

Eli Lilly profits more than double as weight-loss drug sales soar

Financial Times · Apr 30, 2026, 12:04 PM · Also reported by 3 other sources

First-quarter sales of medication Zepbound increased 80 per cent to $4.2bn

Read full story on Financial Times → More top stories

Also covered by

CNBC More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says CNBC FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies CNET Samsung Chip Profits Soar Amid the Tech World's RAM Shortages

Aggregated and edited by the Scoop newsroom. We surface news from Financial Times alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Eli Lilly profits more than double as weight-loss drug sales soar

Also covered by

More in business